Section Arrow
IPHA.NASDAQ
- Innate Pharma SA
Quotes are at least 15-min delayed:2025/07/17 16:43 EDT
After Hours
Last
 --
-- (--)
Bid
1.78
Ask
1.84
High -- 
Low -- 
Volume -- 
Regular Hours
Last
 1.7704
-0.0296 (-1.64%)
Day High 
1.7709 
Prev. Close
1.8 
1-M High
1.9206 
Volume 
2.25K 
Bid
1.78
Ask
1.84
Day Low
1.7509 
Open
1.7509 
1-M Low
1.7 
Market Cap 
165.90M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 1.77 
20-SMA 1.81 
50-SMA 2.02 
52-W High 3.5107 
52-W Low 1.29 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.61/-0.75
Enterprise Value
188.18M
Balance Sheet
Book Value Per Share
0.11
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
12.62M
Operating Revenue Per Share
0.51
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
WINTWindtree Therapeutics Inc.1.05+0.15+16.67%0.84PE
After Hours 1.1 +0.05 +4.76%
ABPAbpro Holdings Inc0.1962-0.022-10.08%-- 
After Hours 0.1961 -0.0001 -0.05%
NCNANuCana plc0.0468-0.0034-6.77%-- 
After Hours 0.0469 +0.0001 +0.21%
ATNF180 Life Sciences Corp1.83+0.9497+107.88%0.11PE
After Hours 1.71 -0.12 -6.56%
MRKRMarker Therapeutics1.92+0.32+20.00%-- 
After Hours 1.92 0 0.00%
Quotes are at least 15-min delayed:2025/07/17 16:43 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.